linagliptin vs sitagliptin
Side-by-side comparison of linagliptin and sitagliptin Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tradjenta
Januvia
Jentadueto XR is a drug that combines linagliptin and metformin. It helps lower blood sugar in adults with type 2 diabetes, along with diet and exercise.
Zituvimet is a combination of two medicines, sitagliptin and metformin. It helps lower blood sugar in adults with type 2 diabetes, along with diet and exercise.
Jentadueto XR is used to improve blood sugar control in adults with type 2 diabetes. It should be used in addition to diet and exercise. It is not for people with type 1 diabetes. It has not been studied in patients with a history of pancreatitis.
Zituvimet is used to treat type 2 diabetes. It helps to control your blood sugar levels when diet and exercise are not enough. Zituvimet is not for people with type 1 diabetes.
This medicine contains two drugs. Linagliptin helps your body release more insulin after you eat. Metformin helps your body use insulin better and reduces sugar production in the liver.
Zituvimet contains sitagliptin, which increases insulin release after you eat and decreases sugar production in your liver. It also contains metformin, which helps your body use insulin better and reduces sugar released from the liver. Together, they help lower your blood sugar levels.
- • Runny nose or sore throat
- • Diarrhea
- • Diarrhea
- • Upper respiratory tract infection (like a cold)
- • Headache
- High blood sugar 1,326
- Diarrhea 1,196
- Nausea 1,138
- Tiredness 1,028
- Difficulty breathing 998
- Increased blood sugar 4,452
- Feeling sick to your stomach 3,787
- Diarrhea 3,470
- The medicine is not working 3,467
- Feeling tired 2,883
Jentadueto XR can cause a serious side effect called lactic acidosis. This is a buildup of lactic acid in your blood. Get medical help right away if you have symptoms like weakness, muscle pain, trouble breathing, stomach pain, dizziness, or a slow or irregular heartbeat. Certain conditions increase your risk, such as kidney problems, drinking a lot of alcohol, or having surgery.
Zituvimet can cause a serious condition called lactic acidosis. This is a buildup of lactic acid in your blood. It can be life-threatening. Get medical help right away if you have symptoms like weakness, muscle pain, trouble breathing, sleepiness, or stomach pain.
Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if Jentadueto XR will harm your unborn baby. Discuss the best way to control your blood sugar during pregnancy with your doctor.
Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if Zituvimet will harm your unborn baby. Talk to your doctor if you are breastfeeding.
Also Compare — Nearby Drugs
Compare linagliptin with
Compare sitagliptin with
How to Read This linagliptin vs sitagliptin Comparison
linagliptin is classified in the DPP-4 Inhibitor drug class, while sitagliptin sits within the DPP-4 Inhibitor class. Because both drugs share the same classification, they are often considered interchangeable in theory — but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, linagliptin has 5,686 submissions while sitagliptin has 18,059. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between linagliptin and sitagliptin — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.